Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
3.810
-0.110 (-2.81%)
Jul 13, 2026, 4:00 PM EDT - Market closed
Opus Genetics Revenue
Opus Genetics had revenue of $2.16M in the quarter ending March 31, 2026, a decrease of -50.64%. This brings the company's revenue in the last twelve months to $11.98M, down -12.22% year-over-year. In the year 2025, Opus Genetics had annual revenue of $14.20M with 29.15% growth.
Revenue (ttm)
$11.98M
Revenue Growth
-12.22%
P/S Ratio
26.25
Revenue / Employee
$427,964
Employees
28
Market Cap
314.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.20M | 3.20M | 29.15% |
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 75.00K | - | - |
| Dec 31, 2007 | 75.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 63.50M |
| OmniAb | 28.94M |
| Foghorn Therapeutics | 28.22M |
| Zentalis Pharmaceuticals | 26.87M |
| Lineage Cell Therapeutics | 14.78M |
| InflaRx | 33.82K |
| Lyell Immunopharma | 31.00K |
| Inhibikase Therapeutics | 1.00 |
IRD News
- 4 days ago - Opus Genetics sets September timeline for retinal disease trial data - TheFly
- 5 days ago - Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - GlobeNewsWire
- 7 days ago - Opus Genetics FDA alignment further de-risks path to market, says Chardan - TheFly
- 8 days ago - Opus Genetics announces FDA alignment on OPGx-LCA5 trial - TheFly
- 8 days ago - Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease - GlobeNewsWire
- 17 days ago - Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes - TheFly
- 17 days ago - Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes - GlobeNewsWire
- 21 days ago - Opus Genetics initiated with an Outperform at RBC Capital - TheFly